270 Chapter 8 75. Sandler A, Glesne C, Geller G: Children’s and parents’ perspectives on open-label use of placebos in the treatment of ADHD. Child Care Health Dev 34:111-20, 2008 76. Sandler AD, Bodfish JW: Placebo effects in autism: lessons from secretin. J Dev Behav Pediatr 21:347-50, 2000 77. Colloca L, Finniss D: Nocebo effects, patient-clinician communication, and therapeutic outcomes. JAMA 307:567-8, 2012 78. Kleine-Borgmann J, Bingel U: Nocebo Effects: Neurobiological Mechanisms and Strategies for Prevention and Optimizing Treatment. Int Rev Neurobiol 138:271-283, 2018 79. Mulligan K, Kassoumeri L, Etheridge A, et al: Mothers’ reports of the difficulties that their children experience in taking methotrexate for Juvenile Idiopathic Arthritis and how these impact on quality of life. Pediatr Rheumatol Online J 11:23, 2013 80. Warris LT, van den Heuvel-Eibrink MM, Aries IM, et al: Hydrocortisone does not influence glucocorticoid sensitivity of acute lymphoblastic leukemia cells. Haematologica 100:e137-9, 2015 81. Bostrom BC, Sensel MR, Sather HN, et al: Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children’s Cancer Group. Blood 101:3809-17, 2003 82. Jones B, Freeman AI, Shuster JJ, et al: Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol 19:269-75, 1991 83. Mitchell CD, Richards SM, Kinsey SE, et al: Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 129:734-45, 2005 84. Veerman AJ, Hahlen K, Kamps WA, et al: High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol 14:911-8, 1996 85. Balis FM, Lester CM, Chrousos GP, et al: Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. J Clin Oncol 5:202-7, 1987 86. Inaba H, Pui C-H: Glucocorticoid use in acute lymphoblastic leukaemia. The Lancet Oncology 11:1096-1106, 2010 87. Teuffel O, Kuster SP, Hunger SP, et al: Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Leukemia 25:1232-8, 2011 88. Abelson D, Baron DN, Toakley JG: Studies of cerebrospinal fluid following oral administration of cortisone acetate or hydrocortisone. J Endocrinol 12:87-92, 1955 89. Grossmann C, Scholz T, Rochel M, et al: Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. Eur J Endocrinol 151:397-406, 2004 90. Ito C, Evans WE, McNinch L, et al: Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. J Clin Oncol 14:2370-6, 1996 91. Kaspers GJL, Veerman AJP, PoppSnijders C, et al: Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. Medical and Pediatric Oncology 27:114-121, 1996 92. Styczynski J, Wysocki M, Balwierz W, et al: In vitro comparative antileukemic activity of various glucocorticoids in childhood acute leukemia. Neoplasma 49:178-83, 2002
RkJQdWJsaXNoZXIy MTk4NDMw